Gemcitabine-Ebeve, 10 mg/ml 20 ml

Antitumor agent.

It has cytostatic action which is connected with inhibition of DNA synthesis. In the cell it is metabolized to active diphosphate and triphosphate nucleosides.

Diphosphate nucleosides inhibit the action of ribonucleotide reductase, with the participation of which deoxynucleoside triphosphates necessary for DNA synthesis are formed in the cell, which leads to a decrease in their concentration in the cell.

Triphosphate nucleosides actively compete for inclusion in the DNA chain and can also be incorporated into RNA.

After intracellular gemcitabine metabolites are incorporated into the DNA chain, one additional nucleotide is added to its growing strands, resulting in complete inhibition of further DNA synthesis and programmed cell death.

Indications

Non-small cell lung cancer (stages IIIa-IV); advanced pancreatic carcinomas.

Active ingredient

Composition

Concentrate for preparation of solution for infusion 1 ml gemcitabine 10 mg

How to take, the dosage

Set individually, depending on the indications and stage of the disease, the state of the hematopoiesis system, the scheme of anti-tumor therapy.

Interaction

The risk and severity of leukopenia and thrombocytopenia increases after prior therapy with cytostatics.

Special Instructions

It has some activity in the late stages of breast, ovarian, kidney, bladder and prostate cancer, small cell lung cancer.

With caution it is used in patients with disorders of the hematopoiesis processes; disorders of liver and/or kidney function. During the treatment period the peripheral blood picture should be monitored regularly.

In case of development of toxic hematological effect the dosage regimen should be corrected depending on the degree of leukopenia and thrombocytopenia. Safety and efficacy of gemcitabine use in children has not been studied.

Contraindications

Hypersensitivity to gemcitabine.

Side effects

Blood system disorders: leukopenia, thrombocytopenia, anemia.

Digestive system disorders: nausea, vomiting, diarrhea; rarely – constipation.

As to the urinary system: proteinuria, hematuria; rarely – peripheral edema; in rare cases – renal failure.

Dermatological reactions: skin rash, itching, alopecia, stomatitis; rarely – scaling, vesicular rash, eczema.

Laboratory measures: transient increase of liver transaminases activity, alkaline phosphatase, increased concentration of bilirubin in plasma.

Respiratory system disorders: rare – bronchospasm, dyspnea.

CNS and peripheral nervous system disorders: rarely – somnolence, weakness, paresthesia.

Cardiovascular system: rare – arterial hypotension, pulmonary edema; in single cases – myocardial infarction, arrhythmia.

Other: flu-like syndrome.

Similarities